ijms-logo

Journal Browser

Journal Browser

Special Issue "Dissecting the Interactions between Cancer, Heart and Anticancer Drug Cardiotoxicity 2.0"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Toxicology".

Deadline for manuscript submissions: 30 November 2021.

Special Issue Editors

Dr. Carlo Gabriele Tocchetti
E-Mail
Guest Editor
Department of Translational Medical Sciences, Federico II University, Via Pansini 5, Edificio 2, 80131 Naples, NA, Italy
Interests: cardio-oncology; heart failure
Special Issues, Collections and Topics in MDPI journals
Dr. Flora Pirozzi
E-Mail
Co-Guest Editor
Department of Translational Medical Sciences, Federico II University, 80131 Naples, Italy
Interests: Keywords: heart failure, cardio-oncology
Dr. Valentina Mercurio
E-Mail
Co-Guest Editor
Affiliation: Department of Translational Medical Sciences, Federico II University, 80131 Naples, Italy
Interests: Keywords: heart failure, cardio-oncology, cardio-pulmonary diseases

Special Issue Information

Dear Colleagues,

With the prolongation in life expectancy, a continuously ageing population is more prone to developing chronic diseases. The prevalence of cardiovascular and oncologic disorders is also increasing, and there is an unmet need for life-saving treatments. This Special Issue is calling for original articles and state-of-the-art reviews that address the mechanisms and the clinical scenarios linking cancer, cardiovascular disorders and conventional and novel oncological therapies, in order to update the readers of IJMS with the major advancements in this field. Basic and clinical research are upfront in dissecting the complex, bidirectional interactions between cancer and cardiovascular disorders that frequently lead to an increased risk of cardiotoxicity from antineoplastic drugs, and in the quest for novel therapeutic strategies to fight these problems.

Assoc. Prof. Carlo Gabriele Tocchetti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Impact of the Pd2Spm (Spermine) Complex on the Metabolism of Triple-Negative Breast Cancer Tumors of a Xenograft Mouse Model
Int. J. Mol. Sci. 2021, 22(19), 10775; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms221910775 - 05 Oct 2021
Viewed by 338
Abstract
The interest in palladium(II) compounds as potential new anticancer drugs has increased in recent years, due to their high toxicity and acquired resistance to platinum(II)-derived agents, namely cisplatin. In fact, palladium complexes with biogenic polyamines (e.g., spermine, Pd2Spm) have been known [...] Read more.
The interest in palladium(II) compounds as potential new anticancer drugs has increased in recent years, due to their high toxicity and acquired resistance to platinum(II)-derived agents, namely cisplatin. In fact, palladium complexes with biogenic polyamines (e.g., spermine, Pd2Spm) have been known to display favorable antineoplastic properties against distinct human breast cancer cell lines. This study describes the in vivo response of triple-negative breast cancer (TNBC) tumors to the Pd2Spm complex or to cisplatin (reference drug), compared to tumors in vehicle-treated mice. Both polar and lipophilic extracts of tumors, excised from a MDA-MB-231 cell-derived xenograft mouse model, were characterized through nuclear magnetic resonance (NMR) metabolomics. Interestingly, the results show that polar and lipophilic metabolomes clearly exhibit distinct responses for each drug, with polar metabolites showing a stronger impact of the Pd(II)-complex compared to cisplatin, whereas neither drug was observed to significantly affect tumor lipophilic metabolism. Compared to cisplatin, exposure to Pd2Spm triggered a higher number of, and more marked, variations in some amino acids, nucleotides and derivatives, membrane precursors (choline and phosphoethanolamine), dimethylamine, fumarate and guanidine acetate, a signature that may be relatable to the cytotoxicity and/or mechanism of action of the palladium complex. Putative explanatory biochemical hypotheses are advanced on the role of the new Pd2Spm complex in TNBC metabolism. Full article
Show Figures

Figure 1

Back to TopTop